Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial

The Lancet Oncology

Volumn 14, Issue 13, 2013, Pages 1307-1316

  Araujo, John C ^a   Trudel, Géralyn C ^b   Saad, Fred ^c   Armstrong, Andrew J ^d   Yu, Evan Y ^e   Bellmunt, Joaquim ^f,g   Wilding, George ^h   McCaffrey, John ⁱ   Serrano, Sergio V ^j   Matveev, Vsevolod B ^k   Efstathiou, Eleni ^l   Oudard, Stephane ^m   Morris, Michael J ⁿ   Sizer, Bruce ^o   Goebell, Peter J ^p   Heidenreich, Axel ^q   de Bono, Johann S ^r   Begbie, Stephen ^s   Hong, Jun H ^t   Richardet, Eduardo ^u   Gallardo, Enrique ^v   Paliwal, Prashni ^b   Durham, Susan ^b   Cheng, Shinta ^b   Logothetis, Christopher J ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d DUKE CANCER INSTITUTE   (United States)

^e SEATTLE CANCER CARE ALLIANCE   (United States)

^f HOSPITAL DEL MAR   (Spain)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF WISCONSIN   (United States)

ⁱ All Ireland Cooperative Oncology Research Group   (Ireland)

^j BARRETOS CANCER HOSPITAL   (Brazil)

^k N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^l UNIVERSITY OF ATHENS   (Greece)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁿ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^o ESSEX COUNTY HOSPITAL   (United Kingdom)

^p UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^q UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^r INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^s PORT MACQUARIE BASE HOSPITAL   (Australia)

^t University of Ulsan   (South Korea)

^u Universidad Catolico de Cordoba   (Argentina)

^v HOSPITAL DE SABADELL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CREATININE; DASATINIB; DOCETAXEL; PLACEBO; PREDNISONE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; EDEMA; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INSOMNIA; LACRIMATION; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRIMIDINES; TAXOIDS; THIAZOLES; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84888130823     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70479-0     Document Type: Article

References (35)

1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
3. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154. for the TROPIC Investigators.
4. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
5. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148.
6. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
7. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
8. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer 2012, 48:678-686.
9. Sturge J, Caley MP, Waxman J Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011, 8:357-368.
10. Dayyani F, Gallick GE, Logothetis CJ, Corn PG Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011, 103:1665-1675.
11. Fizazi K The role of Src in prostate cancer. Ann Oncol 2007, 18:1765-1773.
12. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008, 68:3323-3333.
13. Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R Src kinase activity is essential for osteoclast function. J Biol Chem 2004, 279:17660-17666.
14. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 2009, 15:3540-3549.
15. Mendiratta P, Mostaghel E, Guinney J, et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009, 27:2022-2029.
16. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
17. Araujo JC, Poblenz A, Corn P, et al. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation. Cancer Biol Ther 2009, 8:2153-2159.
18. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 2009, 101:263-268.
19. Luo FR, Barrett YC, Yang Z, et al. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. Cancer Chemother Pharmacol 2008, 62:1065-1074.
20. Luo FR, Barrett Y, Ji P, et al. Dasatinib (BMS-354825) pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003). Proc Am Soc Clin Oncol 2006, 24(suppl). abstr 3046.
21. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009, 15:7421-7428.
22. Araujo JC, Mathew P, Armstrong AJ, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012, 118:63-71.
23. Pocock SJ, Simon R Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
24. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
25. Daut RL, Cleeland CS, Flanery RC Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983, 17:197-210.
26. Cleeland CS The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res 2006, 12:6236s-6242s.
27. Kelly WK, Halabi S, Carducci M, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012, 30:1534-1540.
28. Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol 2013, 14:893-900.
29. Lara PN, Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009, 20:179-184.
30. Antonarakis ES, Heath EI, Posadas EM, et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 2013, 71:883-892.
31. Sonpavde G, Pond GR, Berry WR, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2012, 30:607-613.
32. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
33. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013, 14:760-768. on behalf of the VENICE investigators.
34. Mostaghel EA, Nelson PS Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008, 22:243-258.
35. Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012, 30:637-643.